Intersystem Crossing Rates in Photoexcited Rose Bengal: Solvation versus Isolation

We compare the intersystem crossing rate, kISC, of Rose Bengal (RB) in an aqueous pH 12 solution with the corresponding relaxation rates of four different RB-derived anion and dianion species isolated in the gas phase: the doubly deprotonated dianion ([RB-2H]2–), the singly deprotonated monoanion ([RB-H]−), and the corresponding singly negatively charged sodium and cesium adducts ([RB-2H + Na]− and [RB-2H + Cs]−, respectively). Each of them was probed following photoexcitation of their first singlet excited states (S1) at or near room temperature. The solution was studied by transient absorption spectroscopy, whereas the mass-selected anions were characterized by time-resolved photoelectron spectroscopyall with ca. 50 femtosecond temporal resolution. [RB-H]− shows an S1 lifetime of ca. 80 ps; the solution ensemble, thought to consist primarily of solvated dianion chromophores, shows a similar lifetime of ca. 70 ps. By contrast, the isolated dianion, [RB-2H]2–, has a much longer lifetime. Superimposed on S1 decay attributable mainly to intersystem crossing, all four isolated anions also show some rapid oscillatory features of the transient photoelectron signal on a 4–5 ps timescale after excitation. Interestingly, an analogous phenomenon is also seen in the transient absorption measurements. We attribute it to a librational oscillation as the S1 state, initially populated in the S0 geometry, relaxes into its excited state equilibrium structure. Some implications of these observations for RB photophysics and interpretation of solution measurements are discussedalso in terms of density functional theory and time-dependent density functional theory calculations of ground and excited states

A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. Methods: This was a phase 2, single-arm, open-label, multicentre study (NCT02902965). The primary endpoint was progression-free survival (PFS). Results: Seventy-six patients were enrolled; 74 received ≥1 dose of study treatment. After median follow-up of 19.6 months, median PFS was 8.5 months (95% CI: 6.2-10.8); median overall survival was not reached. Overall response rate was 57% (95% CI: 45-68), and median duration of response was 9.5 months (95% CI: 6.9-10.6). Grade 3/4 AEs occurred in 73% of patients and fatal AEs occurred in 15% of patients. Incidence of major haemorrhage was 5%; one patient died from cerebral haemorrhage. After an observed increased incidence of serious (42%) and fatal (11%) infections, enrolment was suspended to implement risk-minimisation measures. The safety profile was otherwise consistent with known safety profiles of the individual drugs. Conclusion: Ibrutinib combined with bortezomib and dexamethasone elicited clinical responses. However, efficacy assessments conducted at potential restart of enrolment indicated that the targeted PFS could not be reached with additional patient enrolment, and the study was terminated

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

[Purpose]: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. [Methods]: Patients had confirmed symptomatic WM, either previously untreated or previously treated; patients with prior rituximab had at least a minor response to their last rituximab-based regimen. Patients were randomly assigned to once-daily ibrutinib 420 mg plus rituximab or placebo plus rituximab (n = 75 per arm). The primary end point was progression-free survival (PFS). Secondary end points included response rate, time to next treatment, hemoglobin improvement, overall survival, and safety. [Results]: With a median follow-up of 50 (range, 0.5-63) months, median (95% CI) PFS was not reached (57.7 months to not evaluable) with ibrutinib-rituximab versus 20.3 months (13.0 to 27.6) with placebo-rituximab (hazard ratio, 0.250; P < .0001). PFS benefit was regardless of prior treatment status, MYD88 and CXCR4 mutation status, or key patient characteristics. Higher response rates (partial response or better) were observed with ibrutinib-rituximab (76% v 31% with placebo-rituximab; P < .0001) and were sustained over time. Median time to next treatment was not reached with ibrutinib-rituximab versus 18 months with placebo-rituximab. More patients receiving ibrutinib-rituximab versus placebo-rituximab had sustained hemoglobin improvement (77% v 43%; P < .0001). Median overall survival was not reached in either arm. Ibrutinib-rituximab maintained a manageable safety profile; the prevalence of grade ≥ 3 adverse events of clinical interest generally decreased over time. [Conclusion]: In the final analysis of iNNOVATE with a median follow-up of 50 months, ibrutinib-rituximab showed ongoing superiority across clinical outcomes in patients with WM regardless of MYD88 or CXCR4 mutation status, prior treatment, and key patient characteristics.Supported by Pharmacyclics LLC, an AbbVie Company. Pharmacyclics LLC sponsored and designed the study.Peer reviewe

Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

This article provides a short summary of 5-year results from the iNNOVATE trial. The original paper was published in the Journal of Clinical Oncology in October 2021. People with Waldenström's macroglobulinemia (WM) were randomly divided into two groups of 75 people each. One group received a combination treatment composed of two drugs, ibrutinib plus rituximab, and the other group took placebo (“sugar pill”) plus rituximab. Ibrutinib (also known by the brand name Imbruvica®) is a drug that reduces cancer cells' ability to multiply and survive. Ibrutinib is an FDA-approved drug for the treatment of WM. Rituximab is a drug that helps the immune system find and kill cancer cells. Participants in the trial were treated and their health monitored for up to 5 years (63 months).Editorial support for development of this summary was provided by Cindi A. Hoover, PhD, and was funded by Pharmacyclics LLC, an AbbVie Company.Peer reviewe

Dispersion, retardation and scale effect in tracer breakthrough curves in karst conduits

Characteristics of tracer breakthrough curves in karst conduits are examined and compared to results generated using well known equations applied to porous media. The equations of the turbulent dispersion lead to a transport equation similar to the classical advection–dispersion equation for porous media with a slightly different meaning for the dispersion and advection terms. For investigations at the meter length scale, we used a three-dimensional (3-D) computational fluid dynamics (CFD) code to simulate tracer transport in several conduit geometries. The simulations show that turbulent dispersion can be considered as Fickian at a meter length scale of observation and that turbulent dispersivity depends linearly on the average flow velocity in the range of observed velocities. The simulations show that pools induce retardation (tailing of the breakthrough curve) due to flow reversal in eddies. Retardation has a complex relationship with the pool dimensions. Irregularity of the conduit cross-section along the investigated section clearly produces retardation. This is obvious at the meter length scale but may still be visible 103 m downstream from the injection point. A transfer function (“black box”) approach is used for upscaling from a meter to a 103 m length scale. Before applying it to natural examples, the transfer function approach is tested by using the 3-D CFD code and appears to perform well. Several tests, based on numerical, laboratory and field experiments, of conduit segments which includes various dispersive features indicate that retardation tends to be transformed to symmetrical dispersion with distance. At large scale it appears that the dominant dispersion factor is the irregularity of the conduit geometry, which produces an increase in dispersivity with distance (“scale effect”), similar to that observed in porous media. In conclusion this suggests that retardation and high dispersion provide evidence of an irregular conduit, including either numerous dispersive features or large-scale ones (